Author + information
- Adnan Kassier,
- Adam Tawney,
- Paul Nona and
- Karthikeyan Ananthasubramaniam
Background: Ventricular assist devices (VADs) are approved therapy in advanced heart failure population as a bridge to transplant or destination therapy. Echocardiography plays a crucial role in evaluation of VAD function. Echo contrast (EC) agents are commonly used adjuncts for better visualization of cardiac chambers. The safety of EC use and their affect on VAD hemodynamics has not been well studied to our knowledge.
Methods: Retrospective review of 130 patients with VAD who were hospitalized at our institution between 2010-2015. Changes in vital signs, speed, power, pulsatility index (PI) and flow were recorded within 24 hours and also 24-48 hours after EC use. Baseline characteristics, alarms, death, new arrhythmias or worsening heart failure were also recorded.
Results: Our sample patients had 99 Heart Mate II, 26 Heart Ware and 5 Heart Mate III. Median age was 57 + 12.6 and median amount of contrast used was 1.5 + 0.7. There was no statistically significant changes in hemodynamics or VAD interrogation within 24 hours of contrast use. 24-48 hours post contrast was only statistically significant for changes in VAD speed. Results are described in table 1. No significant new arrhythmias or worsening heart failure noted
Conclusions: EC use has no adverse hemodynamic influence on VAD hemodynamics. The mean change in VAD speed was likely related to changes in patient medical condition that is not related to worsening heart failure or new arrhythmias. EC use should follow standard echo indications in VAD patients
Poster Hall, Hall C
Sunday, March 19, 2017, 9:45 a.m.-10:30 a.m.
Session Title: Insights From Echocardiography Use
Abstract Category: 28. Non Invasive Imaging: Echo
Presentation Number: 1291-222
- 2017 American College of Cardiology Foundation